The Brain Cancer Partnering 2007-2012 provides understanding and access to the brain cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of brain cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors lymphoma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This data driven report contains over 70 links to online copies of actual brain cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of brain cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in brain cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading brain cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of brain cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of brain cancer technologies and products.
Brain Cancer Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to brain cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in brain cancer dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
Access to over 70 brain cancer contract documents
The leading brain cancer deals by value since 2007
In Brain Cancer Partnering 2007-2012, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 1 - Introduction
Chapter 2 - Trends in brain cancer partnering
2.2. Brain cancer partnering over the years
2.3. Bigpharma brain cancer dealmaking activity
2.4. Brain cancer partnering by deal type
2.5. Brain cancer partnering industry sector
2.6. Brain cancer partnering by stage of development
2.7. Brain cancer partnering by technology type
2.8. Disclosed financial deal terms for brain cancer partnering
2.8.1 Brain cancer headline values
2.8.2 Brain cancer upfront payments
2.8.3 Brain cancer milestone payments
2.8.4 Brain cancer royalty rates
Chapter 3 - Leading brain cancer deals
3.2. Top brain cancer deals by value
3.3. Top brain cancer deals involving bigpharma
Chapter 4 - Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 - Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 - Deal type definitions
Table of figures
Figure 1: Brain cancer partnering since 2007
Figure 2: Bigpharma - top 50 - brain cancer deals 2007 to 2011
Figure 3: Bigpharma brain cancer deal frequency - 2007 to 2011
Figure 4: Brain cancer partnering by deal type since 2007
Figure 5: Brain cancer partnering by industry sector since 2007
Figure 6: Brain cancer partnering by stage of development since 2007
Figure 7: Brain cancer partnering by technology type since 2007
Figure 8: Brain cancer deals with a headline value
Figure 9: Brain cancer deals with upfront payment values
Figure 10: Brain cancer deals with milestone payments
Figure 11: Brain cancer deals with royalty rates, %
Figure 12: Top brain cancer deals by value since 2007
Figure 13: Top brain cancer deals signed by bigpharma value since 2007
The Alzheimer's Disease Partnering 2007-2012 provides understanding and access to the alzheimer's disease partnering deals and agreements entered into by the worlds leading healthcare companies . Th ...Read More
Angina Partnering 2007-2012 provides understanding and access to the angina partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of ...Read More
The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with an ...Read More
Product description The present Competitive Intelligence Report about Anti-Obesity Peptides and Biologics used to treat obesity and metabolic syndrome provides a competitor evaluation in the field of ...Read More
The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading hea ...Read More
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug p ...Read More
The Anxiety Partnering 2007-2012 provides understanding and access to the anxiety partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an anal ...Read More
Arrhythmia Partnering 2007-2012 provides understanding and access to the arrhythmia partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an ana ...Read More
The Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter asset purchase deals. Product purchase co ...Read More
Atherosclerosis Partnering 2007-2012 provides understanding and access to the atherosclerosis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provi ...Read More
* Required field
For support please
contact: US Toll Free
+1 888-789-6604 Asia Pacific
To receive alerts about
an update, future offers and discounts on this report, signup here. Email ID